NERVGEN PHARMA CORP. Losses On Change In Fair Value Of Derivatives
NERVGEN PHARMA CORP. (NGEN) reported Losses On Change In Fair Value Of Derivatives of CAD 18.96 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Notes › Derivative Instruments and Hedging Activities
ifrs-full:LossesOnChangeInFairValueOfDerivatives · last filed 2026-03-31
| Period end | Losses On Change In Fair Value Of Derivatives 12 month |
|---|---|
| 2025-12-31 | 18.96M CAD 40-F · filed 2026-03-31 |
| 2024-12-31 | 135.96K CAD 40-F · filed 2026-03-31 |